By Fineline Cube 
France’s Pierre Fabre Laboratories has entered into a strategic partnership with Switzerland-based RedRidge Bio AG to identify and develop biparatopic antibody (BPA) drug candidates targeting multiple therapeutic areas. The collaboration, aligned with Pierre Fabre’s innovation strategy, will focus on precision oncology, dermatology, and rare diseases, leveraging the complementary strengths of both companies.
Partnership Structure and Responsibilities
Under the agreement, Red Ridge Bio will be responsible for engineering, screening, and characterizing BPAs against an undisclosed portfolio of jointly nominated targets. Pierre Fabre will support the advancement of two co-development programs through clinical development. Red Ridge Bio will hold exclusive commercial rights in the United States, Canada, and Japan for these programs, while Pierre Fabre will own exclusive rights for the rest of the world. Additionally, Pierre Fabre will acquire exclusive worldwide rights for a third program following a preclinical hand-off from Red Ridge Bio.
Financial Terms and Investment Support
The financial terms of the agreement include an undisclosed upfront payment, milestone payments, and future sales royalties. Pierre Fabre will also fund research payments for its worldwide program and share R&D costs for the co-development programs. In a further show of support, Pierre Fabre will back Red Ridge Bio in its upcoming Series A financing round.-Fineline Info & Tech